aggressive medical treatment-Beijing Tiantan Hospital

aggressive medical treatment-Beijing Tiantan Hospital refers to a specific therapeutic regimen utilized in the DREAM-PRIDE clinical trial (NCT04152707) for the prevention of recurrent stroke in patients with symptomatic intracranial atherosclerotic disease (ICAD). Developed by Beijing Tiantan Hospital, this aggressive protocol is characterized by an intensified dual antiplatelet therapy (DAPT) duration and rigorous risk factor management. The pharmacological component involves the daily administration of aspirin (100 mg) combined with either clopidogrel (75 mg) or ticagrelor (90 mg twice daily) for a period of six months, which is double the duration of standard medical treatment. Additionally, the regimen incorporates comprehensive management of vascular risk factors, including hypertension, diabetes, and dyslipidemia, alongside behavioral interventions such as smoking cessation and structured exercise programs.

Other names

Aggressive medical treatmentAMTAggressive medical treatment (DREAM-PRIDE)